Efficacy and Safety of Clopidogrel Versus Aspirin Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.

IF 3.3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Clinical Medicine Insights. Cardiology Pub Date : 2026-01-18 eCollection Date: 2026-01-01 DOI:10.1177/11795468251414841
Ameer Haider Cheema, Muhammad Hassan Waseem, Zain Ul Abideen, Muhammad Zubair Tahir, Fahad Saleem, Amna Nadeem, Urvah Tauseef, Tahreem Qasim, Sania Aimen, Muhammad Bilal Zahid, Pawan Kumar Thada
{"title":"Efficacy and Safety of Clopidogrel Versus Aspirin Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.","authors":"Ameer Haider Cheema, Muhammad Hassan Waseem, Zain Ul Abideen, Muhammad Zubair Tahir, Fahad Saleem, Amna Nadeem, Urvah Tauseef, Tahreem Qasim, Sania Aimen, Muhammad Bilal Zahid, Pawan Kumar Thada","doi":"10.1177/11795468251414841","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronary artery disease (CAD) is the leading cause of death worldwide. After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is recommended to reduce thrombotic events. This meta-analysis assesses the effectiveness of clopidogrel compared to aspirin monotherapy following DAPT post-PCI.</p><p><strong>Methods: </strong>From inception to April 2025, an exhaustive literature search was conducted across electronic databases, including PubMed, Cochrane Library, ScienceDirect, EMBASE, and Web of Science. Risk ratios (RRs) along with 95% confidence intervals (CIs) were pooled using the random-effects model in Review Manager. Leave-one-out sensitivity analysis and funnel plots were used to evaluate heterogeneity and publication bias, respectively.</p><p><strong>Results: </strong>Six studies, including 3 RCTs and 3 observational studies, spanning over 19 494 patients, were included in our analysis. Clopidogrel significantly reduced major adverse cardiovascular events (MACE) (RR = 0.78; 95% CI: [0.69, 0.89]; <i>P</i> = .0002; <i>I</i> <sup>2</sup> = 0%) and myocardial infarction (MI) (RR = 0.73; 95% CI: [0.56, 0.94]; <i>P</i> = .02; <i>I</i> <sup>2</sup> = 21%) compared to aspirin. Likewise, the clopidogrel group demonstrated a substantial advantage in reducing the incidence of any stroke (RR = 0.66; 95% CI: [0.49, 0.89]; <i>P</i> = .006; <i>I</i> <sup>2</sup> = 14%), including ischemic stroke (RR = 0.69; 95% CI: [0.49, 0.97]; <i>P</i> = .04; <i>I</i> <sup>2</sup> = 0%). All other endpoints, including hemorrhagic stroke, all-cause mortality, cardiac death, major bleeding, stent thrombosis, repeat, and target vessel revascularization, were comparable between the 2 arms.</p><p><strong>Conclusion: </strong>Clopidogrel significantly reduced the incidence of MACE, MI, and stroke after DAPT following PCI compared to aspirin, indicating greater effectiveness. However, the main conclusion of this meta-analysis depends primarily on the estimates from RCTs. Additional randomized studies are necessary to confirm these results and support clinical decision-making.</p>","PeriodicalId":10419,"journal":{"name":"Clinical Medicine Insights. Cardiology","volume":"20 ","pages":"11795468251414841"},"PeriodicalIF":3.3000,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12813258/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795468251414841","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Coronary artery disease (CAD) is the leading cause of death worldwide. After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is recommended to reduce thrombotic events. This meta-analysis assesses the effectiveness of clopidogrel compared to aspirin monotherapy following DAPT post-PCI.

Methods: From inception to April 2025, an exhaustive literature search was conducted across electronic databases, including PubMed, Cochrane Library, ScienceDirect, EMBASE, and Web of Science. Risk ratios (RRs) along with 95% confidence intervals (CIs) were pooled using the random-effects model in Review Manager. Leave-one-out sensitivity analysis and funnel plots were used to evaluate heterogeneity and publication bias, respectively.

Results: Six studies, including 3 RCTs and 3 observational studies, spanning over 19 494 patients, were included in our analysis. Clopidogrel significantly reduced major adverse cardiovascular events (MACE) (RR = 0.78; 95% CI: [0.69, 0.89]; P = .0002; I 2 = 0%) and myocardial infarction (MI) (RR = 0.73; 95% CI: [0.56, 0.94]; P = .02; I 2 = 21%) compared to aspirin. Likewise, the clopidogrel group demonstrated a substantial advantage in reducing the incidence of any stroke (RR = 0.66; 95% CI: [0.49, 0.89]; P = .006; I 2 = 14%), including ischemic stroke (RR = 0.69; 95% CI: [0.49, 0.97]; P = .04; I 2 = 0%). All other endpoints, including hemorrhagic stroke, all-cause mortality, cardiac death, major bleeding, stent thrombosis, repeat, and target vessel revascularization, were comparable between the 2 arms.

Conclusion: Clopidogrel significantly reduced the incidence of MACE, MI, and stroke after DAPT following PCI compared to aspirin, indicating greater effectiveness. However, the main conclusion of this meta-analysis depends primarily on the estimates from RCTs. Additional randomized studies are necessary to confirm these results and support clinical decision-making.

Abstract Image

Abstract Image

Abstract Image

经皮冠状动脉介入治疗后氯吡格雷与阿司匹林单药治疗的疗效和安全性:一项系统综述和荟萃分析。
背景:冠状动脉疾病(CAD)是世界范围内导致死亡的主要原因。经皮冠状动脉介入治疗(PCI)后,推荐双重抗血小板治疗(DAPT)以减少血栓事件。本荟萃分析评估了氯吡格雷与阿司匹林单药治疗pci术后DAPT的疗效。方法:从成立到2025年4月,在PubMed、Cochrane Library、ScienceDirect、EMBASE和Web of Science等电子数据库中进行了详尽的文献检索。使用Review Manager中的随机效应模型汇总风险比(rr)和95%置信区间(ci)。用留一敏感性分析和漏斗图分别评价异质性和发表偏倚。结果:我们的分析纳入了6项研究,包括3项随机对照试验和3项观察性研究,共19494例患者。与阿司匹林相比,氯吡格雷显著降低了主要不良心血管事件(MACE) (RR = 0.78; 95% CI: [0.69, 0.89]; P = 0.0002; i2 = 0%)和心肌梗死(MI) (RR = 0.73; 95% CI: [0.56, 0.94]; P = 0.02; i2 = 21%)。同样,氯吡格雷组在降低各种中风(RR = 0.66; 95% CI: [0.49, 0.89]; P = 0.006; I 2 = 14%),包括缺血性中风(RR = 0.69; 95% CI: [0.49, 0.97]; P = 0.04; I 2 = 0%)的发生率方面显示出显著优势。所有其他终点,包括出血性卒中、全因死亡率、心源性死亡、大出血、支架血栓形成、重复和靶血管重建术,在两组之间具有可比性。结论:与阿司匹林相比,氯吡格雷可显著降低PCI术后DAPT术后MACE、心肌梗死和卒中的发生率,表明氯吡格雷更有效。然而,本荟萃分析的主要结论主要依赖于随机对照试验的估计。需要更多的随机研究来证实这些结果并支持临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Medicine Insights. Cardiology
Clinical Medicine Insights. Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.20
自引率
3.30%
发文量
16
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书